Does using the contraceptive pill increase DVT risk? 

Choosing the right method of contraception is a personal decision that involves weighing benefits against potential health considerations. For many, the combined hormonal contraceptive (CHC) pill is a reliable and effective choice. However, one of the most frequently discussed topics regarding its use is the risk of developing a blood clot, specifically Deep Vein Thrombosis (DVT). 

This article provides a balanced overview of how hormonal contraceptives interact with the body’s clotting mechanisms. You will learn about the statistical likelihood of experiencing a clot, the factors that might increase your individual risk, and how to identify symptoms that require urgent medical attention. Our goal is to provide the clarity needed to make an informed choice in consultation with a healthcare professional. 

What We’ll Discuss in This Article 

• The biological link between synthetic hormones and blood viscosity. 

• Comparing the risk levels between different generations of the pill. 

• Individual risk factors such as age, BMI, and smoking. 

• Environmental triggers like long-distance travel and surgery. 

• How to distinguish DVT symptoms from common leg discomfort. 

• Expert insights on the latest 2026 safety data for newer formulations. 

Understanding Blood Clot Risks Associated With the Contraceptive Pill 

Using combined hormonal contraception (CHC) does slightly increase the risk of developing a blood clot compared to those not using these methods. The absolute risk remains very small for most people. Research shows that while roughly 2 in 10,000 women not using the pill develop a clot each year, this figure rises to between 5 and 12 in 10,000 for those using combined hormonal methods. 

The primary reason for this increase is the presence of synthetic oestrogen, which can alter the balance of clotting factors produced by the liver. This makes the blood slightly more likely to stick together and form a thrombus. It is important to note that the risk is still significantly lower than the risk of developing a clot during pregnancy or the postpartum period. 

• First-Year Window: The risk is statistically highest during the first 6 to 12 months of starting the pill or after a break of four weeks or more. 

• Progestogen Influence: The specific type of progestogen in the pill also affects the risk level; older generations (like levonorgestrel) generally carry a lower risk than some newer formulations. 

• Reversibility: Once a person stops taking the pill, the associated increase in clotting risk typically returns to baseline levels within a few weeks. 

Clinical guidance suggests that for the vast majority of healthy individuals, the benefits of effective contraception and cycle management far outweigh the small increase in VTE risk. 

Causes of Increased Clotting Risk 

The physiological cause of increased risk is the ‘pro-thrombotic’ effect of oestrogen on the blood’s chemical makeup. When taken orally, synthetic oestrogens pass through the liver, where they stimulate the production of proteins that encourage clotting while decreasing the activity of natural anticoagulants. 

Specific causes that can further elevate this risk include: 

• Hormonal Concentration: Higher doses of oestrogen are generally linked to a higher risk profile. 

• Genetic Predisposition: Individuals with undiagnosed blood disorders, such as Factor V Leiden, have a much higher response to hormonal changes. 

• Hormonal ‘Generation’: ‘Second-generation’ pills containing levonorgestrel are often considered the baseline for safety, whereas ‘third’ and ‘fourth’ generation pills may have a slightly higher relative risk. 

Triggers for DVT while on the Pill 

While the pill provides the physiological setting for a clot, external triggers often act as the catalyst. Being aware of these situations allows users to take extra precautions. 

• Long-Duration Travel: Sitting for more than 4 hours on a flight or car journey slows blood flow in the legs. 

• Surgery and Recovery: Major operations or being confined to bed (immobility) significantly increases the chance of blood pooling and clotting. 

• Dehydration: As noted by Dr. Stefan, a lack of fluids can lead to hemoconcentration, making the blood more viscous and prone to clumping. 

• Smoking: Tobacco use damages the blood vessel lining and, when combined with the pill, exponentially increases the risk of both venous and arterial clots. 

Differentiation: Muscle Strain vs. DVT Symptoms 

It is common to experience occasional leg aches, but a blood clot requires a different response. Knowing the ‘unilateral’ (one-sided) nature of DVT is key. 

Feature	Muscle Strain/Cramp	Deep Vein Thrombosis (DVT)
Location	Often felt in the muscle belly; may be in both legs.	Usually localised to one leg, often the calf or thigh.
Skin Temperature	Skin temperature remains normal.	The affected area feels warm or hot to the touch.
Appearance	No visible change or occasional bruising.	Redness, darkening, or blue/purple discolouration.
Pain Character	Sharp during movement; improves with rest.	Persistent throbbing or heavy aching; worse when standing.
Swelling	Minimal or localised to an injury site.	Significant swelling of the entire calf or leg.

Conclusion 

In summary, while the contraceptive pill does increase the risk of DVT, the absolute risk for a healthy individual is very low. Most people can safely use the pill for many years without issue. Staying active, maintaining a healthy weight, and not smoking are the most effective ways to mitigate the small risk associated with hormonal contraception. 

If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article was written by our Medical Content Team and reviewed by Dr. Rebecca Fernandez, a UK-trained physician with an MBBS and extensive experience in cardiology and internal medicine. Dr. Fernandez has a background in managing acute trauma and critically ill patients, ensuring that this guide provides medically accurate and safe information regarding hormonal health. This article is designed to support informed decision-making through evidence-based clinical insights.